News

Real-world use of the extended half-life factor replacement therapy Elocta (efmoroctocog alfa) was associated with better bleed control than standard half-life products among people with hemophilia A, according to findings from an observational study in Europe. Elocta, sold as Eloctate in the U.S., was also associated with fewer…

People with hemophilia are more likely to be infected with the SEN virus (SENV), which is associated with blood transfusion hepatitis, or liver inflammation, than healthy people, a study in Iran suggests. The virus was detected in more than half of patients with hemophilia A and most commonly in…

Hympavzi (marstacimab-hncq) may be available by prescription in the U.S. before the end of the year. The therapy was approved this month as a routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages 12 and older, with hemophilia A or…

A European Medicines Agency (EMA) committee has recommended the approval of Novo Nordisk’s concizumab as a prophylactic, or preventive, treatment for adults and children, ages 12 and older, with hemophilia A or B who have inhibitors. The recommendation, from the EMA’s Committee for Medicinal Products for Human Use…

Sevenfact (eptacog beta) was deemed safe and effective at stopping bleeds in patients with hemophilia A or B with inhibitors, according to real-world data from a case series study in the U.S. The treatment was also more affordable than other similar therapies and effective even in patients who’d failed…

The Spanish Interministerial Commission on the Pricing of Medicines, known as CIPM, has issued a positive recommendation for national reimbursement of Hemgenix (etranacogene dezaparvovec) for eligible people with hemophilia B, according to CSL Behring, the company that markets the gene therapy. The recommendation means that patients in Spain should…

The U.S. Food and Drug Administration (FDA) has approved Pfizer’s marstacimab under the brand name Hympavzi for use as a routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages 12 and older, with hemophilia A or B without inhibitors. With…

Hemophilia gene therapy Beqvez (fidanacogene elaparvovec), marketed as Durveqtix in the European Union, results in stable production of factor IX (FIX), the clotting protein that is missing or faulty in hemophilia B, leading to about three times fewer bleeding episodes compared with prophylaxis, or preventive treatment, with regular infusions…

Immunotherapy is an effective treatment strategy to suppress the production of autoantibodies and induce remission in people with acquired hemophilia A, a small study in China suggests. In some cases, however, multiple cycles of immunosuppressive treatment may be required for patients to achieve a good treatment response.The results were published…

Hemlibra (emicizumab) effectively prevented bleeds in patients with acquired hemophilia A (AHA), according to real-world data from a single center study in Japan. The treatment also led to shorter hospital stays, helped patients maintain their daily living activities, and contributed to lower the doses of bypassing agents,…